BR112018016874A2 - métodos e composições para distribuição de arilsulfatase a no sistema nervoso central (snc) - Google Patents

métodos e composições para distribuição de arilsulfatase a no sistema nervoso central (snc)

Info

Publication number
BR112018016874A2
BR112018016874A2 BR112018016874A BR112018016874A BR112018016874A2 BR 112018016874 A2 BR112018016874 A2 BR 112018016874A2 BR 112018016874 A BR112018016874 A BR 112018016874A BR 112018016874 A BR112018016874 A BR 112018016874A BR 112018016874 A2 BR112018016874 A2 BR 112018016874A2
Authority
BR
Brazil
Prior art keywords
methods
arylsulfatase
snc
distributing
compositions
Prior art date
Application number
BR112018016874A
Other languages
English (en)
Inventor
Wijatyk Anna
Wasilewski Margaret
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of BR112018016874A2 publication Critical patent/BR112018016874A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

são fornecidos métodos de tratamento da leucodistrofia metacromática que compreendem a administração, a um sujeito em necessidade de tratamento, de uma quantidade terapeuticamente eficaz da enzima arilsulfatase a recombinante.
BR112018016874A 2016-02-17 2017-02-17 métodos e composições para distribuição de arilsulfatase a no sistema nervoso central (snc) BR112018016874A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662296563P 2016-02-17 2016-02-17
US201762453864P 2017-02-02 2017-02-02
PCT/US2017/018440 WO2017143233A1 (en) 2016-02-17 2017-02-17 Methods and compositions for cns delivery of arylsulfatase a

Publications (1)

Publication Number Publication Date
BR112018016874A2 true BR112018016874A2 (pt) 2019-02-05

Family

ID=58192404

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018016874A BR112018016874A2 (pt) 2016-02-17 2017-02-17 métodos e composições para distribuição de arilsulfatase a no sistema nervoso central (snc)

Country Status (10)

Country Link
US (2) US11020461B2 (pt)
EP (1) EP3416678A1 (pt)
JP (3) JP2019509270A (pt)
CN (2) CN108883162A (pt)
AU (1) AU2017220100B2 (pt)
BR (1) BR112018016874A2 (pt)
CA (1) CA3014909A1 (pt)
MA (1) MA44237A (pt)
MX (1) MX2018009937A (pt)
WO (1) WO2017143233A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111699249A (zh) * 2017-12-19 2020-09-22 夏尔人类遗传性治疗公司 纯化的芳基硫酸酯酶a及其组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US9320711B2 (en) * 2010-06-25 2016-04-26 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of heparan N-sulfatase
RU2626514C2 (ru) * 2010-06-25 2017-07-28 Шир Хьюман Дженетик Терапис, Инк. Доставка к цнс лечебных агентов
PL3626257T3 (pl) * 2010-06-25 2022-03-28 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania arylosulfatazy a do oun
WO2011163649A2 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc Methods and compositions for cns delivery of iduronate-2-sulfatase

Also Published As

Publication number Publication date
WO2017143233A1 (en) 2017-08-24
JP2019509270A (ja) 2019-04-04
CA3014909A1 (en) 2017-08-24
AU2017220100A1 (en) 2018-08-30
JP2021169528A (ja) 2021-10-28
JP2023159405A (ja) 2023-10-31
US20200179492A1 (en) 2020-06-11
US20210315981A1 (en) 2021-10-14
AU2017220100B2 (en) 2024-04-04
CN117224659A (zh) 2023-12-15
US11020461B2 (en) 2021-06-01
MA44237A (fr) 2021-06-02
MX2018009937A (es) 2018-11-29
EP3416678A1 (en) 2018-12-26
CN108883162A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2019011219A (es) Administracion rapida y controlada de composiciones con efectos sequito restaurados.
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
MX2018005829A (es) Composiciones para tratar el cabello.
BR112017027506A2 (pt) agentes, usos e métodos para o tratamento da sinucleinopatia
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX2022016422A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
BR112018004680A2 (pt) método de tratamento de distúrbios de desenvolvimento
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112019024566A2 (pt) inibidores de pirazol magl
MX2018013973A (es) Metodos de tratamiento de sindromes de comportamiento usando pipradrol.
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
BR112017018198A2 (pt) inibição da atividade de olig2
UY34896A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
MX2018010196A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
BR112015022196A2 (pt) composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
BR112017018758A2 (pt) alteração do metabolismo de esteroide para tratamento de doença dependente de esteroide
BR112016004904A8 (pt) moduladores de receptor x do fígado (lxr), composição farmacêutica, seus usos e método para modular atividade de lxr

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: SHIRE HUMAN GENETIC THERAPIES, INC. (US)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2648 DE 05/10/2021 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]